Plain-English translation of NCT07362186 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 3 β Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new treatment approach for advanced stomach cancer using two medications: LM-108 (an immune-targeting drug) combined with toripalimab (an immunotherapy). You would be randomly assigned to receive either this new combination or the standard chemotherapy drug paclitaxel. The study wants to see if the new combination works better and is safer than the current standard treatment.
Many people with advanced stomach cancer don't respond well enough to existing treatments, or they experience serious side effects. This study is exploring whether a newer approach using immune system-boosting medications might offer better outcomes for patients whose tumors have the CCR8 marker.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would visit the research clinic regularly for infusions of your assigned treatment (either the new medication combination or paclitaxel) and for blood work and imaging scans to monitor how well the treatment is working and track any side effects. The study involves 400 participants total across multiple hospitals. Your treatment would continue as long as it is helping and you can tolerate it, and the research team would follow your progress closely throughout the study period and for some time after treatment ends.
AI-generated summary from trial data Β· Jun 4, 2026 Β· Not medical advice
China